Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Huiyu Pharmaceuticals: Injectable Carfilzomib Obtains Drug Registration Certificate
Huiyu Pharmaceutical Announcement: Recently, the company received the “Drug Registration Certificate” for its product, Carfilzomib for Injection, approved and issued by the National Medical Products Administration.
The main indication for Carfilzomib for Injection is multiple myeloma.
The original branded product, Carfilzomib by Onyx Pharmaceuticals, Inc., has been launched in China.
As of now, seven domestic companies hold the approval documents for Carfilzomib for Injection and have passed or are deemed to have passed the consistency evaluation of quality and efficacy for generic drugs, including Huiyu Pharmaceutical, Jiangsu Hengrui Medicine, Qilu Pharmaceutical, and Zhengda Tianqing Pharmaceutical.